HPS2-THRIVE results: Bad for niacin/laropiprant, good for ezetimibe?

Atherosclerosis

Volumn 229, Issue 2, 2013, Pages 449-450

  Masana, L ^a   Cabre A ^a   Plana, N ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Ezetimibe; HPS2 THRIVE; LDL; Niacin

Indexed keywords

EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; LAROPIPRANT; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PLACEBO; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG TARGETING; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RISK REDUCTION;

EZETIMIBE; HPS2-THRIVE; LDL; NIACIN;

ADAPTOR PROTEIN COMPLEX 3; ADAPTOR PROTEIN COMPLEX BETA SUBUNITS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; HUMANS; HYPOLIPIDEMIC AGENTS; INDOLES; NIACIN; SIMVASTATIN;

EID: 84880601226     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.06.006     Document Type: Article

References (3)

1. Villines T.C., Stanek E.J., Devine P.J., Turco M., Miller M., Weissman N.J., et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. JAm Coll Cardiol 2010, 55:2721-2726.
2. Kastelein J.J., Akdim F., Stroes E.S., Zwinderman A.H., Bots M.L., Stalenhoef A.F., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. NEngl J Med 2008, 358:1431-1443. ENHANCE Investigators.
3. Baigent C., Landray M.J., Reith C., Emberson J., Wheeler D.C., Tomson C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192. SHARP Investigators.